RU2436590C1 - Применение альфа-1-антитрипсина для получения лекарственных средств для лечения синдрома хронической усталости - Google Patents
Применение альфа-1-антитрипсина для получения лекарственных средств для лечения синдрома хронической усталости Download PDFInfo
- Publication number
- RU2436590C1 RU2436590C1 RU2010126653/15A RU2010126653A RU2436590C1 RU 2436590 C1 RU2436590 C1 RU 2436590C1 RU 2010126653/15 A RU2010126653/15 A RU 2010126653/15A RU 2010126653 A RU2010126653 A RU 2010126653A RU 2436590 C1 RU2436590 C1 RU 2436590C1
- Authority
- RU
- Russia
- Prior art keywords
- aat
- cfs
- alpha
- antitrypsin
- patients
- Prior art date
Links
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title claims abstract description 96
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title claims abstract description 95
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title claims abstract description 94
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title claims abstract description 83
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title claims abstract description 81
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 230000037396 body weight Effects 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 16
- 238000005516 engineering process Methods 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 21
- 102000016387 Pancreatic elastase Human genes 0.000 abstract description 18
- 108010067372 Pancreatic elastase Proteins 0.000 abstract description 18
- 230000015556 catabolic process Effects 0.000 abstract description 7
- 238000006731 degradation reaction Methods 0.000 abstract description 7
- 210000002381 plasma Anatomy 0.000 abstract description 6
- 230000003834 intracellular effect Effects 0.000 abstract description 5
- 208000010877 cognitive disease Diseases 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000001149 cognitive effect Effects 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 210000005087 mononuclear cell Anatomy 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 33
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 33
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 208000001640 Fibromyalgia Diseases 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 230000017854 proteolysis Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 206010014561 Emphysema Diseases 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102000008102 Ankyrins Human genes 0.000 description 5
- 108010049777 Ankyrins Proteins 0.000 description 5
- 102000003792 Metallothionein Human genes 0.000 description 5
- 108090000157 Metallothionein Proteins 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 4
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101710152894 ATP-binding cassette sub-family E member 1 Proteins 0.000 description 3
- 102100020969 ATP-binding cassette sub-family E member 1 Human genes 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710114283 Translation initiation factor RLI1 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000007114 proinflammatory cascade Effects 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000027626 Neurocognitive disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010057244 Post viral fatigue syndrome Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 102100029698 Metallothionein-1A Human genes 0.000 description 1
- 101710196493 Metallothionein-1E Proteins 0.000 description 1
- 102100037514 Metallothionein-1F Human genes 0.000 description 1
- 101710196495 Metallothionein-1F Proteins 0.000 description 1
- 102100031742 Metallothionein-1H Human genes 0.000 description 1
- 101710196486 Metallothionein-1H Proteins 0.000 description 1
- 102100031781 Metallothionein-1X Human genes 0.000 description 1
- 101710196503 Metallothionein-1X Proteins 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 101710196499 Metallothionein-2A Proteins 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000051631 human SERPINA1 Human genes 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010011767 m-calpain Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940075461 other therapeutic product in atc Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200930387 | 2009-06-30 | ||
| ES200930387A ES2332645B1 (es) | 2009-06-30 | 2009-06-30 | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2436590C1 true RU2436590C1 (ru) | 2011-12-20 |
Family
ID=41571181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010126653/15A RU2436590C1 (ru) | 2009-06-30 | 2010-06-29 | Применение альфа-1-антитрипсина для получения лекарственных средств для лечения синдрома хронической усталости |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9205134B2 (https=) |
| EP (1) | EP2289540B1 (https=) |
| JP (1) | JP5231490B2 (https=) |
| CN (1) | CN101934071B (https=) |
| AR (1) | AR077123A1 (https=) |
| AU (1) | AU2010202203B2 (https=) |
| BR (1) | BRPI1002087B1 (https=) |
| CA (1) | CA2706212C (https=) |
| CL (1) | CL2010000575A1 (https=) |
| ES (2) | ES2332645B1 (https=) |
| MX (1) | MX2010006125A (https=) |
| NZ (1) | NZ585890A (https=) |
| PL (1) | PL2289540T3 (https=) |
| PT (1) | PT2289540E (https=) |
| RU (1) | RU2436590C1 (https=) |
| UY (1) | UY32670A (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2840475C2 (ru) * | 2021-05-03 | 2025-05-26 | Ажероникс Са | Альфа-1-антитрипсин (ААТ) в лечении и (или) профилактике неврологических нарушений |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014014751A8 (pt) * | 2011-12-19 | 2017-07-04 | Lfb Usa Inc | composição compreendendo alfa-1-antitripsina, células epiteliais de glândula mamária, mamífero não humano transgênico, e, método para reduzir a atividade de elastase no pulmão |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| US20220160847A1 (en) * | 2020-11-20 | 2022-05-26 | Mark Egly | Method of preventing and/or treating a plurality of diseases |
| WO2023184473A1 (zh) * | 2022-04-01 | 2023-10-05 | 首创生物技术有限公司 | 肽用于治疗神经退行性疾病或改善认知功能的用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| WO1998005350A1 (en) * | 1996-08-08 | 1998-02-12 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing diseases |
| WO2000051623A2 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
| WO2008143633A2 (en) * | 2007-01-10 | 2008-11-27 | University Of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
| US7459532B2 (en) * | 2003-05-12 | 2008-12-02 | Bristol-Myers Squibb Company | Variants of the TRP channel family member, LTRPC3G |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2281222A (en) * | 1941-09-27 | 1942-04-28 | American Bosch Corp | Speed regulator for internal combustion engines |
| WO2001081343A2 (en) * | 2000-04-21 | 2001-11-01 | Pharmacia & Upjohn Company | Compounds for treating fibromyalgia and chronic fatigue syndrome |
| WO2002006837A1 (en) * | 2000-07-14 | 2002-01-24 | Matsushita Electric Industrial Co., Ltd. | Particle-labeled protein and immuno-chromatograph using the same |
| AU2003286258B2 (en) | 2002-11-20 | 2006-12-21 | Arriva-Prometic Inc. | Composition and method for treating inflammatory diseases using protease inhibitors |
| US7850970B2 (en) * | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| WO2006026837A1 (en) * | 2004-09-07 | 2006-03-16 | Patrick Englebienne | Diagnostic methods for measuring elastase activity levels |
| ES2281222B1 (es) | 2004-09-24 | 2008-06-01 | Grifols, S.A. | Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia. |
| MX2010003113A (es) * | 2007-09-25 | 2010-04-01 | Abbott Lab | Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina. |
| HUE030205T2 (en) | 2007-11-02 | 2017-05-29 | Grifols Therapeutics Inc | A method, composition, and product for providing alpha-1-antitrypsin |
-
2009
- 2009-06-30 ES ES200930387A patent/ES2332645B1/es not_active Expired - Fee Related
-
2010
- 2010-05-20 ES ES10380071T patent/ES2392691T3/es active Active
- 2010-05-20 PT PT103800710T patent/PT2289540E/pt unknown
- 2010-05-20 EP EP10380071A patent/EP2289540B1/en active Active
- 2010-05-20 PL PL10380071T patent/PL2289540T3/pl unknown
- 2010-05-27 UY UY0001032670A patent/UY32670A/es not_active Application Discontinuation
- 2010-05-28 AU AU2010202203A patent/AU2010202203B2/en active Active
- 2010-06-02 NZ NZ585890A patent/NZ585890A/en not_active IP Right Cessation
- 2010-06-02 CL CL2010000575A patent/CL2010000575A1/es unknown
- 2010-06-03 MX MX2010006125A patent/MX2010006125A/es active IP Right Grant
- 2010-06-04 CA CA2706212A patent/CA2706212C/en active Active
- 2010-06-17 AR ARP100102142A patent/AR077123A1/es unknown
- 2010-06-24 BR BRPI1002087-0A patent/BRPI1002087B1/pt not_active IP Right Cessation
- 2010-06-24 US US12/822,764 patent/US9205134B2/en active Active
- 2010-06-29 JP JP2010147994A patent/JP5231490B2/ja active Active
- 2010-06-29 RU RU2010126653/15A patent/RU2436590C1/ru active
- 2010-06-30 CN CN2010102168418A patent/CN101934071B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| WO1998005350A1 (en) * | 1996-08-08 | 1998-02-12 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing diseases |
| WO2000051623A2 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
| US7459532B2 (en) * | 2003-05-12 | 2008-12-02 | Bristol-Myers Squibb Company | Variants of the TRP channel family member, LTRPC3G |
| WO2008143633A2 (en) * | 2007-01-10 | 2008-11-27 | University Of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
Non-Patent Citations (2)
| Title |
|---|
| Alpha 1-Antitrypsin RN: 9041-92-3 [онлайн] [найдено 2011-04-04] (Найдено из базы данных ChemlDplus). Fregonese L. et al. Hereditary alpha-1-antitrvpsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008 Jun 19;3:16. [онлайн] [найдено 2011-04-04] Найдено из базы данных PubMed PMID: 18565211. Schmechel DE et al. Strategies for dissecting genetic-environmental interactions in neurodegenerative disorders. Neurotoxicology. 2006 Sep; 27(5):637-57. Реферат [онлайн] [найдено 2011-04-05] Найдено из базы данных PubMed PMID: 16870258. Wachter AM et al. Treatment of atopic dermatitis with alpha 1-proteinase inhibitor. Ann Allergy. 1992 Nov; 69(5):407-14. Реферат [онлайн] [найдено 2011-04-05] Найдено из базы данных PubMed PMID: 1456482. Torpy DJ et al. Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab. 2001 Aug; 86(8):3692-700. [онлайн] [найдено 2011-04-04] Найдено из базы дан * |
| Малашенкова И.К. и др. Синдром хронической усталости // Русский медицинский журнал от 17 июня 1997 г., т.5, №12 [онлайн] [найдено 2011-04-05] Найдено из базы данных YANDEX. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2840475C2 (ru) * | 2021-05-03 | 2025-05-26 | Ажероникс Са | Альфа-1-антитрипсин (ААТ) в лечении и (или) профилактике неврологических нарушений |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ585890A (en) | 2011-11-25 |
| AR077123A1 (es) | 2011-08-03 |
| AU2010202203A1 (en) | 2011-01-20 |
| CL2010000575A1 (es) | 2011-10-28 |
| US9205134B2 (en) | 2015-12-08 |
| US20100331261A1 (en) | 2010-12-30 |
| CA2706212C (en) | 2014-02-04 |
| BRPI1002087A2 (pt) | 2012-03-13 |
| EP2289540B1 (en) | 2012-08-22 |
| AU2010202203B2 (en) | 2012-08-23 |
| EP2289540A1 (en) | 2011-03-02 |
| MX2010006125A (es) | 2011-01-05 |
| ES2332645B1 (es) | 2010-10-18 |
| PL2289540T3 (pl) | 2013-03-29 |
| ES2392691T3 (es) | 2012-12-12 |
| CN101934071B (zh) | 2012-11-28 |
| CN101934071A (zh) | 2011-01-05 |
| JP2011012060A (ja) | 2011-01-20 |
| UY32670A (es) | 2011-01-31 |
| BRPI1002087B1 (pt) | 2019-07-02 |
| CA2706212A1 (en) | 2010-12-30 |
| HK1148198A1 (en) | 2011-09-02 |
| PT2289540E (pt) | 2012-12-04 |
| JP5231490B2 (ja) | 2013-07-10 |
| ES2332645A1 (es) | 2010-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2436590C1 (ru) | Применение альфа-1-антитрипсина для получения лекарственных средств для лечения синдрома хронической усталости | |
| RU2006145899A (ru) | Ферменты для фармацевтического применения | |
| WO2003063780A3 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
| KR20130073036A (ko) | Ｎ-아세틸-ｌ-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물 | |
| CN103649106A (zh) | 用于治疗神经退行性和缺血性脑疾病的化合物和药学组合 | |
| US7470666B2 (en) | Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome | |
| US7291595B2 (en) | Use of Alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia | |
| US9775850B2 (en) | Composition and method for curing migraine headaches | |
| HK1148198B (en) | Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome | |
| RU2580657C1 (ru) | Способ лечения больных риносинуситом | |
| Millichap | PANDAS, Tics and OCD, and Immunotherapy | |
| UA137135U (uk) | Спосіб лікування хворих на хронічний панкреатит з метаболічним синдромом | |
| Khilnani et al. | Management of severe sepsis: Role of" Bundles" | |
| Alavi-Naini et al. | Aspergillous sinusitis | |
| Section | TREATMENT OF SUDDED DEAFNESS WITH RADIX PUERARIADE: A COMPARATIVE ANALYSIS OF THERAPEUTIC RESULTS IN 294 CASES | |
| MD118Y (ro) | Metoda de tratament al bolii pulmonare obstructive cronice la persoanele de varsta inaintata | |
| HK1083601B (en) | Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia | |
| WO2017106288A1 (en) | Novel compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy |